Abstract
The mechanisms underlying possible increased HIV-1 acquisition in adenovirus 5 (Ad5)-seropositive subjects vaccinated with Ad5-HIV-1 vectors in the Merck STEP trial remain unclear. We find that Ad5 serostatus does not predict Ad5-specific CD4(+) T cell frequency, and we did not observe durable significant differences in Ad5-specific CD4(+) T cells between Ad5-seropositive and Ad5-seronegative subjects after vaccination. These findings indicate no causative role for Ad5-specific CD4(+) T cells in increasing HIV-1 susceptibility in the STEP trial.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Research Support, N.I.H., Extramural
MeSH terms
-
AIDS Vaccines / immunology*
-
Acquired Immunodeficiency Syndrome / blood
-
Acquired Immunodeficiency Syndrome / diagnosis
-
Acquired Immunodeficiency Syndrome / immunology
-
Acquired Immunodeficiency Syndrome / therapy*
-
Adenoviridae / immunology*
-
Antibodies, Viral / blood*
-
CD4 Lymphocyte Count
-
CD4-Positive T-Lymphocytes / immunology*
-
Cell Proliferation
-
HIV-1 / immunology
-
Humans
-
Prognosis
-
T-Cell Antigen Receptor Specificity / immunology*
-
Vaccines, Synthetic / immunology
Substances
-
AIDS Vaccines
-
Antibodies, Viral
-
Vaccines, Synthetic